JMP Securities lowered the firm’s price target on OptimizeRx (OPRX) to $8 from $16 and keeps an Outperform rating on the shares. OptimizeRx reported a disappointing Q3 miss and guide-down, but JMP continues to like the company’s end-to-end HCP-direct-to-consumer platform, its continued Dynamic Audience Activation Platform momentum, the embedded growth opportunity represented by cross-selling its portfolio of brands, and the scalability of the model, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OPRX:
- OptimizeRx price target lowered to $5 from $11 at Barclays
- OptimizeRx Reports Strong Revenue Growth in Q3 2024
- Closing Bell Movers: Tetra Tech down 8% after Q4 results, guidance
- OptimizeRx sees FY24 revenue $88M-$92M , consensus $100.69M
- OptimizeRx reports Q3 EPS 12c, consensus 6c
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
